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Intravenous (IV) lipids should comprise between 30% and 
50% of all nonnitrogen calories. However, the refinement and 
development of IV fat emulsions (IVFEs) have been complex.1 
All IVFEs provided in the United States are derived from soy-
bean oil and are predominately long-chain triglyceride (LCT) 
ω-6 polyunsaturated fatty acids (FAs) and thus, in certain set-
tings, have been shown to drive a proinflammatory response. 
To address these potential shortcomings, other sources of 
fat emulsions (FEs), including medium-chain triglycerides 
(MCTs), can reduce the total amount of LCTs delivered to the 
patient. Additional advantages of MCTs include greater solubi-
lization of the lipid component, decreased accumulation of lip-
ids in the liver, and improved clearance and reduced production 
of proinflammatory mediators.2,3 In addition, use of MCTs 
may actually improve immune function by decreasing the lev-
els of tumor necrosis factor–α (TNF-α).4 Another strategy is 
the replacement of soybean-predominant FE with an olive oil–
predominant fat. Use of agents with 80% olive oil can reduce a 
patient’s exposure to ω-6 FAs. Furthermore, olive oils contain 
a blend of ω-3, ω-6, and ω-9 FAs and other antioxidants, 
including polyphenols. Another alternative FE strategy has 
been to use fish oil. A fish oil FE is composed of almost entirely 
ω-3 FAs and may also prevent a proinflammatory state.5
The ideal IVFE remains elusive, and gaining the ideal bal-
ance of FAs may have tremendous implications for patient out-
comes, including mortality.6,7 Comparisons of FAs have 
identified that even clinically approved IVFEs can lead to 
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Abstract
Background: Injectable fat emulsions (FEs) are a clinically dependable source of essential fatty acids (FA). ω-6 FA is associated with 
an inflammatory response. Medium-chain triglycerides (MCT, ω-3 FA), fish oil, and olive oil are reported to decrease the inflammatory 
response. However, the effect of these lipids on the gastrointestinal tract has not been well studied. To address this, we used a mouse 
model of parenteral nutrition (PN) and hypothesized that a decrease in intestinal inflammation would be seen when either fish oil and 
MCT or olive oil were added. Methods: Three FEs were studied in adult C57BL/6 mice via intravenous cannulation: standard soybean-
based FE (SBFE), 80% olive oil -supplemented FE (OOFE), or a combination of a soybean oil, MCT, olive oil, and fish oil emulsion 
(SMOF). PN was given for 7 days, small bowel mucosa-derived cytokines, animal survival rate, epithelial cell (EC) proliferation and 
apoptosis rates, intestinal barrier function and mucosal FA composition were analyzed. Results: Compared to the SBFE and SMOF 
groups, the best survival, highest EC proliferation and lowest EC apoptosis rates were observed in the OOFE group; and associated with 
the lowest levels of tumor necrosis factor-α, interleukin-6, and interleukin-1β expression. Jejunal FA content showed higher levels of 
eicosapentaenoic and docosapentaenoic acid in the SMOF group and the highest arachidonic acid in the OOFE group. Conclusion: The 
study showed that PN containing OOFE had beneficial effects to small bowel health and animal survival. Further investigation may help 
to enhance bowel integrity in patients restricted to PN. (JPEN J Parenter Enteral Nutr. 2013;37:775-786)
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essential FA deficiencies, and thus further optimization of for-
mulas is needed.8 Use of such alternative FEs has shown prom-
ising effects in reducing a proinflammatory injury in the liver.9 
However, although many of these now commercially available 
FEs have been studied in terms of their system effects, little is 
known regarding the action of these fats on the intestinal epi-
thelium. This has significant implications as the administration 
of parenteral nutrition (PN) results in significant loss of intes-
tinal epithelial barrier function (EBF) and profound intestinal 
mucosal atrophy10; these changes have been associated with a 
marked increase in the mucosal expression of several proin-
flammatory cytokines.11 However, it is unknown if different 
IVFEs can influence these adverse changes. To address this, 
we used a mouse PN model and hypothesized that a decrease 
in intestinal inflammatory-linked cytokines and intestinal atro-
phy would be seen when alternative IVFEs were added to 
existing soybean lipid emulsions, thereby reducing the total 
exposure to soybean oil.
Methods
PN Animal Model
Male specific pathogen-free (SPF) C57BL/6J mice (10–12 
weeks old; Jackson Laboratory, Bar Harbor, ME) were main-
tained under temperature-, humidity-, and light-controlled con-
ditions. Mice were initially fed ad libitum with standard mouse 
chow and water and allowed to acclimate for 1 week prior to 
surgery. During the administration of IV solutions, mice were 
housed in metabolic cages to prevent coprophagia. Studies 
conformed to guidelines for care established by the University 
Committee on Use and Care of Animals at the University of 
Michigan, and protocols were approved by that committee 
(No. 03986). Methods of cannulation and PN infusion were 
similar to that previously described.12-14 The control group 
received an IV crystalloid solution (dextrose 5% in 0.45 NS 
with 20 mEq KCl/L) at 0.3 mL/h and standard laboratory 
mouse chow. The PN groups received an IV PN solution at 7.2 
mL/24 hours but were allowed water ad libitum. All study 
groups had complete nutrient supplementation, with all essen-
tial vitamins, trace elements, and minerals being supplied; 
details of caloric delivery have been published in this journal.15 
All animals received similar daily energy and nitrogen delivery 
and were euthanized at 7 days using CO
2
. The small intestine 
was exposed from the ligament of Treitz. We discarded the first 
5 cm of jejunum and then took 2 cm of jejunum for FA analy-
sis, 1 cm of jejunum for RNA extraction, another 2 cm for his-
tology, and 4 cm for Ussing chamber testing (Suppl. Fig. S1).
IVFE and Study Masking
Three IVFEs were studied (n = 8/group) in adult C57BL/6 
mice via IV cannulation: standard soybean-based FE (SBFE), 
olive oil–supplemented FE (OOFE; composed of 80% olive oil 
and 20% soybean oil), and a combination soybean oil (30%), 
medium-chain triglycerides (30%), olive oil (25%), and fish oil 
emulsion (15%) (SMOF). To ensure a nonbiased approach, the 
FEs were initially masked so that investigators did not know 
(ie, were blinded) the identity of the FEs until the data analysis 
was completed. These 3 groups were compared with a sham or 
chow-fed group of mice. All FEs were derived from commer-
cial products as follows: SBFE (Intralipid; Fresenius Kabi, 
Uppsala, Sweden), OOFE (Clinoleic; Baxter Healthcare, 
Deerfield, IL), and SMOF (SMOFlipid, Fresenius Kabi). Each 
FE was studied at 3 concentrations, comprising 10%, 20%, or 
30% of total daily energy delivery as fat. Compensation of 
energy delivery between groups was provided by the addition 
or subtraction of dextrose to ensure each group was isocaloric, 
isonitrogenous, and isovolemic. All volumes, energy delivery, 
and nitrogen concentrations were balanced between all study 
groups. Furthermore, all solutions were compounded by a ster-
ile, class 100,000 facility at our university (HomeMed Infusion 
Company) as a 3:1 solution.
Intestinal Morphology Assessment
Villus height and crypt depth were measured in at least 20 
well-oriented full-length crypt-villus units per specimen and 
averaged. Data were analyzed using commercially available 
digital image analysis software NIS-Elements, AR 3.0 (Nikon 
Instruments Inc, Melville, NY).
Epithelial Cell Proliferation and Apoptosis
For epithelial cell (EC) proliferation, immunofluorescent stain-
ing for proliferating cell nuclear antigen (PCNA) was per-
formed as previously described.16 Results are expressed as the 
ratio of the number of PCNA-positive cells to the total number 
of crypt cells. A total of 15–20 crypts were measured for each 
mouse. EC proliferation was also measured with BrdU stain-
ing, as previously described.17 Immunofluorescent staining for 
active caspase-3 was performed to assess EC apoptosis, as pre-
viously described.10 Results are expressed as an apoptotic 
index (% active caspase-3–positive cell number/villi cell num-
ber, using a mean of 10–15 villi/mouse).
Real-Time Polymerase Chain Reaction
RNA extraction of jejunum mucosal scrapings was processed 
as previously described.10 Oligomers were designed using an 
optimization program (www.premierBiosoft.com). Real-time 
polymerase chain reaction was performed and normalized to 
β-actin.18
Immunofluorescence Microscopy
A 0.5-cm section of fresh jejunum (~10 cm from the ligament 
of Treitz) was harvested and immunofluorescence staining was 
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performed as previously described.19 Fluorescence was ana-
lyzed by using an Olympus BX-51 upright light and fluores-
cence microscope (Olympus, Center Valley, PA), and images 
were stacked using Nikon image software (Nikon, Tokyo, 
Japan) and processed using Adobe Photoshop CS4 (Adobe, 
San Jose, CA).
Epithelial Barrier Function
Full-thickness jejunal tissue was mounted in Ussing chambers. 
Assessment of EBF was measured using previously described 
methods.11 Jejunum transepithelial resistance (TER) was deter-
mined by measurements of spontaneous voltage and isoelectric 
current using the Ohms law after a 30-minute equilibration 
period and was expressed Ω·cm2.
FA Analysis
After mice jejunum tissue, which had been frozen at −80°C, 
was slowly warmed, a 150-g piece was cut and transferred to a 
blood collection tube (100 × 16 mm). The weight (mg) of the 
tissue piece was recorded and then put on ice. Then, 1.0 mL of 
cooled phosphate-buffered saline was added to the tube, and 
the sample was homogenized with an Omni homogenizer and 
Omni-Tips (Omni international homogenizer company, 
Kennesaw, GA) for 30 minutes and then put back on ice. Next, 
100 µL of jejunum homogenate was transferred to a disposable 
glass tube (16 × 100 mm; Pyrex with Teflon-lined screw caps). 
To these tubes, 20 µL of tricosanoic acid (C23:0, 0.989 mg/
mL) as an internal standard and 2000 µL of methanol-benzene 
4:1 (v/v) were then added. The tubes were vortexed gently. 
Tubes were placed in a dry ice bath for 10 minutes. Then, 250 
µL of acetyl chloride was added to each tube while on dry ice, 
the caps were tightly closed, and the tube rack was transferred 
at room temperature (RT) until the reaction mixture had melted. 
The tubes were then vortexed gently. The tubes were purged 
with nitrogen gas, with the Teflon-lined caps tightly closed 
again, and subjected to RT for 24 hours. The tubes were cooled 




 solution was 
added slowly to stop the reaction and neutralize the mixture. 
The reaction mixture was vortexed and then centrifuged at 
3000 rmp for 20 minutes (25°C) to separate layers. An aliquot 
(150–200 µL) was removed by gently tilting the tubes and 
drawing off the benzene layer with a hand pipettor, using the 
long-tailed pipet tips. The contents were transferred in the sam-
ple vials (amber color with glass inserts) for gas chromatogra-
phy (GC) analysis. For each sample, peaks were identified 
based on the retention time compared with the corresponding 
reference standards; peak area was determined for each FA 
methyl ester, including C23:0 methyl ester (as internal stan-
dard), from the GC chromatograph.20 FA methyl ester concen-
trations in the sample were normalized and calculated relative 
to that of the internal standard (C23:0) and tissue amount.
Data Analysis
Data were expressed as mean ± standard deviation (SD). 
Statistical analysis employed paired t tests for comparison of 2 
means and a 1-way analysis of variance (ANOVA) for com-
parison of multiple groups (with a Bonferroni post hoc analysis 
to assess statistical differences between groups), and 2-way 
ANOVA test was used for categorical data (Prism software; 
GraphPad Software, San Diego, CA). Statistical significance 
was defined as P < .05.
Results
Preliminary studies were performed with FE concentrations 
being studied at 10%, 20%, and 30%. Due to the complexity of 
reporting the results, we believed that the most clinically rele-
vant percentage that would report the bulk of the results was 
30% of total daily calories as fat, as this approximates a typical 
level added to PN solutions. As well, this percentage was most 
similar to that previously studied by our research group. 
Additional results at the 10% and 20% FE concentrations are 
reported in Table 1.
Survival and Body Weight
Survival rates were compared with mice in each group (Figure 
1A). Sham mice had a 100% survival after the 7-day study 
period. Distinct differences in survival were noted between the 
FE groups. Mice in the SBFE group had an approximately 65% 
survival, which was similar to our previously reported rate of 
70%.16,21,22 Mice in the SMOF group, although not statistically 
different from the SBFE group, had a lower survival rate 
(55%). Interestingly, mice in the OOFE group had the highest 
survival rate (100%), and rates were identical to the 100% sur-
vival of the chow-fed controls.
Body weight loss occurred in all PN mice, as has been 
reported previously (Figure 1B).10,21 The range of weight loss 
was 4–5 g over the 1-week infusion period, and although sig-
nificantly greater than sham (chow-fed) mice, no differences 
were identified between the FE groups.
Intestinal Morphology and Epithelial Cell 
Turnover
As previously reported, administration of PN led to a signifi-
cant degree of intestinal atrophy. Table 1 shows that villus 
height decreased significantly in all PN-treated groups com-
pared with the sham group. The greatest decline was found in 
the SBFE group. Although lower than the sham group, the 
SMOF and OOFE groups both had longer villus lengths com-
pared with the SBFE group. No significant differences were 
seen in the crypt depth between the study groups.
Since PN-associated villus atrophy is due to a loss of EC 
proliferation and an increase in EC apoptosis,23,24 we 
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investigated both. Figure 2 shows EC apoptosis rates, as 
measured by active caspase-3 staining in the 30% FE groups 
compared with enteral controls (sham). Note that EC apopto-
sis rates rose significantly (3-fold greater than the sham 
group) in the SBFE group. Rates of apoptosis were 
somewhat lower in the SMOF group (not significantly dif-
ferent), and levels declined significantly in the OOFE group 
to rates similar to those seen in the sham group.
EC proliferation rates were examined using 2 methods, 
PCNA (Figure 3A) and BrdU (Figure 3B) immunofluores-
cent staining. Both methods showed similar findings, includ-
ing a significant decline in EC proliferation rates between all 
study groups vs shams. However, between the 3 FE groups, 
differences were seen. Of note, EC proliferation rates were 
significantly higher in the 30% OOFE group compared with 
the SBFE group (for PCNA), and when evaluated by BrdU 
staining, the EC proliferation rates in OOFE mice were sig-
nificantly higher compared with both the SBFE and SMOF 
groups.
To better address the mechanisms that may have led to these 
changes, several gene factors associated with EC proliferation 
and apoptosis were examined (Figure 4). Interestingly, despite 
the SBFE group having the lowest EC proliferation rate and 
greatest degree of atrophy, messenger RNA (mRNA) expres-
sion of EGF, although not significantly different, was actually 
highest in the SBFE group and lowest in the OOFE group. The 
EGF receptor, ErbB1, significantly decreased in the SMOF and 
OOFE groups, and epiregulin and transforming growth factor–
α (TGF-α) significantly declined in the OOFE group (Figure 
4C,D). Thus, the precise mechanism that led to improved EC 
proliferation is not clearly identified.
Intestinal Muscosal Gene Expression
mRNA expression of several proinflammatory factors and 
junctional proteins was examined in each study group, and dis-
tinct differences were noted (Figures 5 and 6). SBFE adminis-
tration was associated with the upregulation of TNF-α, TNF 
receptor 1 (TNFR1), interleukin (IL)–1β, and IL-6. In addition, 
SBFE was associated with an upregulation of Toll-like recep-
tor 4 (Tlr4). Somewhat surprisingly, although the SMOF group 
was associated with slightly lower proinflammatory cytokine 
abundances, SMOF was associated with an increase in TNF-α 
abundance. In contrast, the OOFE group was associated with a 
Table 1. Summary of Key Clinical and Cytokine Data.
Group Sham SBFE 10% SMOF 10% OOFE 10% SBFE 20% SMOF 20% OOFE 20% SBFE 30% SMOF 30% OOFE 30%
Crypt depth 22.2 ± 1.9 23.5 ± 1.1 24.1 ± 0.6 23.5 ± 1.1 22.8 ± 0.5 17.2 ± 1.7 28.6 ± 1.5 24.9 ± 1.3 16.3 ± 0.8 25.1 ± 2.1
Villus height 251.3 ± 74 160.9 ± 18.0 218.8 ± 32.4 196.3 ± 22.9 206.1 ± 51.5 192.2 ± 5.5 189.0 ± 14.9 165.7 ± 16.7 168.5 ± 23.1 183.0 ± 14.7
PCNA 0.42 ± 0.03 0.14 ± 0.03 0.12 ± 0.03 0.24 ± 0.04 0.24 ± 0.02 0.25 ± 0.05 0.25 ± 0.05 0.22 ± 0.04 0.24 ± 0.05 0.28 ± 0.02
TNF-αa 0.30 ± 0.07 0.49 ± 0.30 0.95 ± 0.79 0.44 ± 0.21 0.42 ± 0.22 0.38 ± 0.12 0.19 ± 0.08 0.42 ± 0.15 0.69 ± 0.16 0.34 ± 0.20
TNF-R1a 67.0 ± 12.8 96.4 ± 18.8 116.6 ± 36.5 73.0 ± 22.1 111.9 ± 29.6 74.8 ± 11.6 52.3 ± 21.5 134.7 ± 39.6 79.5 ± 18.7 43.6 ± 6.2
IL-1βa 3.37 ± 2.22 4.84 ± 3.89 3.89 ± 2.60 2.46 ± 1.44 6.08 ± 4.28 2.39 ± 2.48 1.30 ± 1.03 5.87 ± 3.04 2.66 ± 1.49 1.67 ± 1.37
IL-6a 0.25 ± 0.12 0.30 ± 0.23 0.73 ± 0.25 0.16 ± 0.16 0.26 ± 0.15 0.22 ± 0.09 0.15 ± 0.07 0.45 ± 0.23 0.11 ± 0.11 0.09 ± 0.04
INF-γa 0.19 ± 0.09 0.51 ± 0.03 1.33 ± 0.93 0.43 ± 0.35 0.14 ± 0.05 0.60 ± 0.29 0.18 ± 0.05 0.26 ± 0.19 0.26 ± 0.11 0.22 ± 0.15
Tlr4a 0.59 ± 0.09 1.01 ± 0.30 1.41 ± 0.90 0.43 ± 0.20 0.56 ± 0.28 0.19 ± 0.09 0.50 ± 0.33 1.08 ± 0.36 0.68 ± 0.23 0.57 ± 0.32
IL, interleukin; INF-γ, interferon γ; OOFE, 80% olive oil–supplemented fat emulsion; PCNA, proliferating cell nuclear antigen; SBFE, standard soy-
bean-based fat emulsion; SMOF, combination of soybean oil, medium-chain triglycerides, olive oil, and fish oil emulsion; TNF, tumor necrosis factor.
aMultiplied by 1000.
Figure 1. Different fat emulsions significantly affected mouse 
survival. (A) Date of death was recorded for mice over the 7 days 
of study. The results are recorded on a survival curve. Of note 
was a significantly improved survival rate in the 30% OOFE 
group (100% survival) compared with the SBEF and SMOF 
groups. (B) Body weight was recorded before and after the 1 
week of PN administration. No significant differences were noted 
between the PN groups. OOFE, 80% olive oil–supplemented 
fat emulsion; PN, parenteral nutrition; SBFE, standard soybean-
based fat emulsion; SMOF, combination of soybean oil, medium-
chain triglycerides, olive oil, and fish oil emulsion.
Feng et al 779
significant decline in all proinflammatory cytokines and Tlr4, 
which were elevated in the SBFE group. No significant changes 
were noted in the abundance of interferon (INF)–γ in any of the 
treatment groups.
mRNA expression of various tight junction markers was 
measured (Figure 6A–C). Levels of each tight junction factor 
varied with the type of FE. Abundance of occludin and ZO-1 
levels increased in the SBFE group, with a significant decline 
in the SMOF and OOFE groups. Similarly, claudin-2 was also 
increased in the SBFE group (approximately 3-fold higher than 
the sham group; Figure 6C), as previously reported,21,25 and 
2-fold higher than sham mice in the SMOF and OOFE groups. 
Claudin-15, however, was associated with a significant decline 
in all FE groups (Figure 6C). The overall increase in claudin-2 
is consistent with its overall pore-forming action with a resul-
tant loss of barrier function. As well, not shown was a global 
decrease in claudin-7 abundance in all FE groups.
EBF and Intestinal FA Content
Barrier function was then measured in Ussing chambers 
(Figure 6D). Interestingly, despite the increase in occludin and 
ZO-1, TER results demonstrated a significant decline in levels 
for all FE groups, and there were no differences noted between 
the groups.
Finally, tissue was collected to analyze the FA content in 
proximal intestinal tissue. Table 2 shows the summary of these 
results at the 30% FE level, with total levels essentially the 
same between the groups. In general, trends followed regard-
less of the dosage of FE given. The results showed that the 
sham (enterally fed) group had somewhat higher levels of 
short-chain FAs (SCFAs) than the SBFE group but similar 
oleic acid levels. The sham mice had the highest levels of lin-
oleic and linolenic acids and lowest levels of arachidonic acid 
(AA). Higher levels of eicosapentaenoic acid (EPA) and doc-
osapentaenoic acid (DPA) levels were found in the sham and 
SMOF groups compared with the SBFF and OOFE groups. 
Interestingly, the OOFE group exhibited the highest percent-
age of AA, irrespective of the dosage level.
Discussion
In this article, we examined 3 commercially available IVFEs 
regarding their effect on intestinal mucosal gene expression, 
morphology, epithelial cell turnover, and overall systemic 
effect on body weight and survival. Interestingly, we found dis-
tinct and significant changes between these 3 compounds. 
Overall weight of the mice was not different between groups, 
and outcomes at each percentage of FE varied somewhat 
between groups. However, when focusing the results on the 
30% of energy via the FE group, survival patterns were dra-
matically different. In particular, use of OOFE resulted in a 
nearly 100% survival, whereas SMOF and SBFE resulted in 
far lower survival rates. Although surprising, other groups 
have also identified issues with the use of soybean-based lip-
ids. A comparison of survival between fish oil vs soybean FE 
in a septic rat model demonstrated a significant improvement 
in survival in the fish oil group.26
An area that has not been studied is the effect that FE prod-
ucts might have on intestinal physiology. Although one might 
suspect that matched energy delivery would suffice to yield 
Figure 2. EC apoptosis rates were markedly increased in the 
SBFE PN group. Apoptosis was measured with active caspase-3 
staining in small bowel epithelium. (A) Representative active 
caspase-3 immunofluorescence images from each study group. 
(B) Apoptosis index is the ratio of active caspase-3 cells to the 
total number of epithelial cells. Note that the SBFE group had 
the highest EC apoptosis index and OOFE mice had the lowest 
apoptosis index compared with the SBFE and SMOF groups, 
with levels reaching those of the sham group. EC, epithelial cell; 
OOFE, 80% olive oil–supplemented fat emulsion; PN, parenteral 
nutrition; SBFE, standard soybean-based fat emulsion; SMOF, 
combination of soybean oil, medium-chain triglycerides, olive 
oil, and fish oil emulsion.
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similar outcomes in each group, striking differences were 
noted. When examined at the 30% FE dosing, EC prolifera-
tion was significantly higher and EC apoptosis rates were sig-
nificantly lower in the OOFE group, with a resultant partial 
prevention of PN-associated mucosal atrophy. mRNA analysis 
demonstrated several changes in gene expression that appeared 
somewhat contrary to the EC findings. This included an upreg-
ulation of TCF4/LEF transcription factors cyclin D1 and 
c-Myc in the SBFE group, particularly at the 30% concentra-
tion. In addition, a decline in the stem cell marker LGR5 and 
declines in cyclin D1 and c-Myc were seen in the OOFE group. 
It is possible that the upregulation in the SBFE group is a com-
pensatory attempt to prevent the adverse effects (atrophy) 
occurring with this FE. It may also be an attempt to counter the 
proinflammatory state associated with the infusion of SBFE.
Our findings showed a trend toward a proinflammatory 
cytokine state within the intestinal mucosa in mice given 
SBFE, with reduced levels of these cytokines in the SMOF 
group and even lower levels in OOFE-treated mice. This 
included a rise in IL-1β and IL-6. We were surprised to see the 
increase in TNF-α abundance in the SMOF group. Although 
this lipid is thought to prevent a proinflammatory state, the eti-
ology of this elevation is unknown, and it is possible that the 
unique immune system of the gastrointestinal (GI) tract may 
respond differently to this combination of lipids or may be due 
to the type of substrate provided to either immunocyte, the 
upregulation of Tlr4, or the altered intraluminal bacteria.22 
Although not examined within the GI tract, several studies 
have pointed to a proinflammatory state with soybean oil. In a 
study examining fish oil vs soybean oil FE, a significant 
Figure 3. EC proliferation rates in crypt were markedly decreased with PN administration; EC proliferation rates were measured 
with PCNA and BrdU staining and expressed by the ratio of positive cells numbers compared with the total crypt ECs numbers. (A) 
Representative images of PCNA staining. (B) Ratio of PCNA-positive cells to total number of crypt cells. Note that all PN groups showed 
a reduced PCNA expression compared with the sham group, and improved EC PCNA staining was observed in the OOFE group vs SBFE 
and SMOF groups. BrdU staining (C, D) showed similar results. EC, epithelial cell; OOFE, 80% olive oil–supplemented fat emulsion; 
PCNA, proliferating cell nuclear antigen; PN, parenteral nutrition; SBFE, standard soybean-based fat emulsion; SMOF, combination of 
soybean oil, medium-chain triglycerides, olive oil, and fish oil emulsion.
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improvement in lymphocyte function was identified.26 In 
another study between fish oil vs soybean oil, fish oil led to an 
increase in TH2-based cytokine formation within spleno-
cytes.27 In a clinical study of preterm infants, a reduction of 
IL-6 was observed in patients fed olive oil vs soybean FE.28 
Finally, human leukocytes showed a marked improvement in 
lymphocyte activation in olive oil FE exposed vs soybean FE 
cells.29 Together, this suggests improved immune function and 
a decline in proinflammatory cytokines with either olive oil– 
or fish oil–based FEs. The precise mechanism by which the 
OOFE group had markedly improved survival is unknown. It is 
quite possible that this could be due to an effect of the unique 
antioxidant effect or differences in polyphenol composition. It 
is also possible that the reduced levels of proinflammatory 
cytokines in this lipid group may be a major contributory 
mechanism.
Barrier function has been shown to significantly decline 
with administration of PN.11,12 The assessment of tight junction 
factors, occludin, ZO-1, claudin-2, and claudin-15, demon-
strated some differences between the groups, with a moderate 
increase in occludin, claudin-2, and ZO-1 in the SBFE group 
and a decline in all FE groups for claudin-15. Interestingly, 
TER was noted to be significantly decreased in all FE groups, 
regardless of the mRNA changes in tight junction factors. This 
Figure 4. Changes in ErbB ligands and EGF receptor (EGFR) expression with PN administration.  Messenger RNA expression of ErbB 
ligands and the EGFR was determined with real-time polymerase chain reaction, and expressed as a ratio to β-actin. (A) EGF expression: 
note the slight decline in the SMOF and OOFE groups; however, no changes were significant. (B) EGF expression: note the significant 
decline in the SMOF and OOFE groups. (C) Epiregulin expression: note the significant decline in the OOFE group. (D) TGF-α expression: 
note the significant decline in the OOFE group. EGF, epidermal growth factor; OOFE, 80% olive oil–supplemented fat emulsion; PN, 
parenteral nutrition; SBFE, standard soybean-based fat emulsion; SMOF, combination of soybean oil, medium-chain triglycerides, olive 
oil, and fish oil emulsion; TGF-α, transforming growth factor–α.
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Figure 5. Proinflammatory cytokines and signaling receptors were increased with PN but downregulated with OOFE. Proinflammatory 
cytokines and the selected TNF-α receptor R1 (TNFR1) were measured with real-time polymerase chain reaction and corrected for 
expression by measuring β-actin messenger RNA. (A) TNF-α expression showed that the SMOF group had the highest levels of TNF-α 
(P < .01) compared with either the SBFE or OOFE group. TNFR1 expression was highest in the SBFE group (P < .01), with slightly 
reduced levels in the SMOF group and significantly lower levels in the OOFE group (P < .01). (B) IL-6 and IL-1β expression were both 
significantly increased in the SBFE group. Levels of these cytokines were reduced in the SMOF group to that of a similar range to sham 
mice, and levels were lowest in the OOFE group and declined below that of sham mice (P < .01). (C) INF-γ levels did not significantly 
change between study groups, whereas Tlr4 expression significantly increased in the SBFE group compared with sham mice and was 
significantly decreased in the OOFE group (P < .01). IL, interleukin; INF-γ, interferon γ; OOFE, 80% olive oil–supplemented fat 
emulsion; PN, parenteral nutrition; SBFE, standard soybean-based fat emulsion; SMOF, combination of soybean oil, medium-chain 
triglycerides, olive oil, and fish oil emulsion; TGF-α, transforming growth factor–α; Tlr4, Toll-like receptor 4.
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Figure 6. Jejunal barrier function was decreased with PN administration. EBF was measured by the abundance of selected tight 
junction factors at the mRNA level. EBF was also measured detecting TER in full-thickness jejunal tissue. (A) mRNA levels of tight 
junction factors ZO-1 and occludin rose modestly in the SBFE group and significantly declined in the SMOF and OOFE groups  
(P < .05). (B) Claudin-2 mRNA abundance rose significantly in all PN groups, with the highest abundance noted in the SBFE group 
(P < .05). Claudin-15 mRNA levels were significantly lower than the sham group in all FE study groups (P < .05). (C) TER measures 
showed a significant decline in all FE study groups compared with the sham group (P < .05). EBF, epithelial barrier function; FE, 
fat emulsion; mRNA, messenger RNA; OOFE, 80% olive oil–supplemented fat emulsion; PN, parenteral nutrition; SBFE, standard 
soybean-based fat emulsion; SMOF, combination of soybean oil, medium-chain triglycerides, olive oil, and fish oil emulsion; TER, 
transepithelial resistance.
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is most likely due to the fact that EBF correlates better with the 
actual structural integrity of these factors,30 and these could all 
be disrupted with the measured increase in proinflammatory 
markers and/or loss of mucosal growth factors in the PN 
groups.
Mechanisms that might account for these differences are 
not known. One of the more intriguing findings was the marked 
decline in proinflammatory cytokines in the OOFE group, yet 
a marked decline in the abundance of several growth factors. It 
has been increasingly appreciated over the past 5 years that 
there is a tight transactivation between TNF-α and EGF.31 
However, with PN administration, our group has previously 
reported an increase in TNF-α and a marked loss of EGF and 
several EGF family members.22 It is possible that the increased 
mRNA abundance of TNF-α in the SBFE and SMOF groups 
and loss of EGF in the OOFE group led to the uniform loss of 
EBF in all FE study groups.
The changes in mucosal FAs measured in the present study 
were interesting and may have significant physiologic corre-
lates. For instance, the marked increase in AA in the OOFE 
group could result in enhanced protection of the host, despite 
the loss of EBF. Recently, enhancement of AA levels within the 
small bowel was shown to improve barrier function in an acute 
ischemia model in suckling piglets.32 In contrast, the increase 
in EPA in the SMOF group might help protect the intestine 
from the increase in proinflammatory cytokines, as EPA has 
also been shown to enhance EBF.32
However, the combination of lipids and the precise mecha-
nisms that have resulted in the present findings are complex 
and not fully determined in this study. It is also not clear how 
differing FAs may have affected the intestinal barrier function 
in our study. It has been reported that polyunsaturated FAs 
induce intracellular acidosis, which can decrease the intracel-
lular adenosine triphosphate level and inhibit Ca+2-ATPase. 
The increase in the calcium level activates actomyosin con-
traction through the activation of cytoskeletal stabilization or 
through other processes leading to the opening of the tight 
junctions.33 Some investigators have shown that DHA and 
EPA have a positive effect on impaired EBF induced by IFN-γ 
and TNF.34 However, this was not shown in the current study. 
Therefore, this suggests that other factors may contribute to 
changes in both EC proliferation and injury of barrier function 
in this PN model, and future studies will need to be done.
One important issue was that we selected a 30% lipid dose 
to make this most relevant to the clinical delivery of nutrition. 
This amount of lipid is higher than what most mouse diets 
Table 2. Fatty Acid Content From Jejunal Mucosal Tissue From Mice.
Fatty Acid Sham SBFE 30% SMOF 30% OOFE 30%
Total content of fatty acids from jejunal 
mucosa, mg/g of mucosal tissue
13.97 ± 4.07 (n = 6) 17.60 ± 7.67 (n = 8) 15.56 ± 7.45 (n = 8) 15.70 ± 2.83 (n = 8)
Total content of fatty acids represented as the percent of all fatty acids, mean ± SD
 C16:0 (palmitic acid) 19.649 ± 0.549 15.025 ± 5.828 17.250 ± 1.450 18.027 ± 1.070
 C18:0 (stearic acid) 18.579 ± 1.388 20.020 ± 2.261 19.708 ± 1.597 18.172 ± 1.733
 C18:1ω-9 (oleic acid) 8.760 ± 2.396 9.051 ± 4.611 11.055 ± 3.370 12.135 ± 2.383
 C18:2ω-6 (linoleic acid) 28.425 ± 1.399 24.762 ± 3.306 21.430 ± 1.667 20.238 ± 1.758
 C18:3ω-3 (α linolenic acid) 0.485 ± 0.261 0.209 ± 0.045 0.202 ± 0.214 0.186 ± 0.117
 C20:4ω-6 (arachidonic acid) 8.290 ± 0.996 13.549 ± 1.924 10.490 ± 2.148 13.582 ± 2.899
 C20:5ω-3 (eicosapentaenoic acid) 1.568 ± 0.122 0.616 ± 0.290 2.817 ± 0.594 0.582 ± 0.182
 C22:5ω-3 (docosapentaenoic acid) 0.640 ± 0.087 0.391 ± 0.083 0.951 ± 0.108 0.360 ± 0.049
 C22:6ω-3 (docosahexaenoate) 5.186 ± 0.687 5.945 ± 0.947 6.680 ± 0.717 6.562 ± 0.464
Fatty Acid Sham vs Sham SBFE 30% vs Sham SMOF 30% vs Sham OOFE 30% vs Sham
Ratio of fatty acids compared with value in sham or enterally fed group
 C16:0 1 0.76 0.88 0.92
 C18:0 1 1.08 1.06 0.98
 C18:1ω-9 1 1.03 1.26 1.39
 C18:2ω-6 1 0.87 0.75 0.71
 C18:3ω-3 1 0.43 0.42 0.38
 C20:4ω-6 1 1.63 1.27 1.64
 C20:5ω-3 1 0.39 1.8 0.37
 C22:5ω-3 1 0.61 1.49 0.56
 C22:6ω-3 1 1.15 1.29 1.27
OOFE, 80% olive oil–supplemented fat emulsion; SBFE, standard soybean-based fat emulsion; SMOF, combination of soybean oil, medium-chain 
triglycerides, olive oil, and fish oil emulsion.
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consist of. Although it is possible that a mouse may be less 
tolerant of this higher lipid dose, we felt that the greatest influ-
ence on survival and the proinflammatory state was due to the 
type of lipid, rather than the absolute dose. Whether the present 
findings will translate to a clinical setting remains to be deter-
mined. As an example, a recent double-blind, randomized, 
clinical trial comparing soybean oil vs olive oil FE in an adult 
intensive care setting failed to demonstrate any differences in 
survival or a reduction in infectious complications.35 In con-
trast, a recent systematic review suggested that fish oil lipid 
emulsions resulted in improved infectious outcomes in surgical 
patients.36 Use of a combination FE, SMOF, led to similar if 
not superior results in a prospective controlled double-blind 
study.37 Presently, only 1 class of IVFEs is available in the 
United States, with all being soybean-based products, whereas 
the other 2 FEs studied in this article are available in other 
regions of the world, including Europe, Asia, the Middle East, 
and South America. Based on the findings of this study and 
many other lines of animal and clinical studies, it is increas-
ingly evident that newer forms of FE need to be studied and 
used in the United States. Such a position recently has been 
taken by the American Society for Parenteral and Enteral 
Nutrition, and it is hoped that such efforts will lead to improved 
nutrition care for those patients receiving PN.38 One limitation 
of this study was that we confined our expression of cytokine 
abundance and growth factors to the mRNA level. To take this 
to the protein level would far exceed the scope of the present 
study, but it will be important to carry this further in future 
investigations. Another limitation was that we focused on 30% 
of nutrients being delivered as an FE. Although this may be 
clinically relevant to humans, it is higher than what most 
rodents use on a daily basis. Thus, a perfect correlation with 
the use of this model is not completely possible.
The implications of this work are considerable in that the 
clinical application and selection of one type of IV lipid over 
another is not readily clear, and the insights provided here 
might help a clinician select one form over another or decide in 
which clinical setting a particular FE may be most appropriate. 
Clearly, these results are confined to the intestine, and a broader 
examination of the physiologic effects of these lipids will need 
to be performed.
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